Post-Marketing Surveillance of REMSIMA 100mg (Infliximab) (monoclonal antibody, gene recombination) to Evaluate Its Safety and Efficacy in Korea (REMSIMA_PMS)

First published 09/09/2015

Last updated 23/04/2024

EU PAS number:

EUPAS10911

Study

Finalised

Documents

Study protocol

Initial protocol

REMSIMA_PMS_v5.0_eng (2)

English (790.86 KB - PDF)View document

Study results

REMSIMA-PMS_Re-examination report_final_1

English (7.53 MB - PDF)View document

Study report

REMSIMA-PMS_Re-examination report_final_2

English (7.17 MB - PDF)View document

REMSIMA-PMS_Re-examination report_final_3

English (7.59 MB - PDF)View document

REMSIMA-PMS_Re-examination report_final_4

English (7.35 MB - PDF)View document

Other information

Study, other information

REMSIMA-PMS_Re-examination report_final_3.pdf

English (7.59 MB - PDF)View document

REMSIMA-PMS_Re-examination report_final_4.pdf

English (7.35 MB - PDF)View document

Secondary tabs